Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > The longer big pharma waits the greater the chance they wili
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1345)
•••
Comment by CancerSlayeron Jun 22, 2024 6:34pm
146 Views
Post# 36101880

RE:RE:The longer big pharma waits the greater the chance they wili

RE:RE:The longer big pharma waits the greater the chance they wili
CancerSlayer wrote:
Agree, but a BTD would help change that dynamic...there would be just too much to ignore (& too much to gain) with that degree of derisking, especially considering the oncology field generally has the highest BTD approval percentage.  Per a report from Pink Sheet 16 April 2021, two-thirds of Breakthrough Therapy Deignations resulted in successful FDA approvals.

The BTD truly represents a significant turning point in a company's trajectory towards approval.  Compared to Fast Track status, meeting the BTD criteria will more accurately tell Big Pharma that this is the real deal & warrants more serious consideration & timely access to patients.  All JMO.  Staying very optimistic...



Clarification:  

Two-thirds of BTDs "in the oncology space" resulted in FDA approvals...when considering the other top fields combined, the percentage is around 40% (per Pink Sheet 16 April 2021).
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities